Beyond Meat (BYND) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Cover Page Document

Cover Page Document - shares	9 Months Ended
	Sep. 28, 2019	Nov. 11, 2019
Cover page.
Entity Registrant Name	BEYOND MEAT, INC.
Document Quarterly Report	true
Document Transition Report	false
Document Type	10-Q
Document Period End Date	Sep. 28, 2019
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Incorporation, State or Country Code	DE
Entity Central Index Key	0001655210
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	false
Entity Ex Transition Period	false
Entity File Number	001-38879
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Amendment Flag	false
Entity Common Stock, Shares Outstanding		61,521,912
Entity Tax Identification Number	26-4087597
Entity Address, Address Line One	119 Standard Street
Entity Address, City or Town	El Segundo
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90245
City Area Code	866
Local Phone Number	756-4112
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	BYND
Security Exchange Name	NASDAQ

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 312,451	$ 54,271
Accounts receivable	34,482	12,626
Inventory	60,270	30,257
Prepaid expenses and other current assets	11,742	5,672
Total current assets	418,945	102,826
Property, plant, and equipment, net	35,050	30,527
Other non-current assets, net	846	396
Total assets	454,841	133,749
Current liabilities:
Accounts payable	38,348	17,247
Wages payable	1,433	1,255
Accrued bonus	3,181	2,312
Accrued expenses and other current liabilities	4,113	2,391
Short-term borrowings under revolving credit line and bank term loan	9,087	0
Short-term capital lease liabilities	30	44
Stock warrant liability	0	1,918
Total current liabilities	56,192	25,167
Long-term liabilities:
Revolving credit line	0	6,000
Long-term portion of bank term loan, net	16,503	19,388
Equipment loan, net	4,922	5,000
Capital lease obligations and other long-term liabilities	396	404
Total long-term liabilities	21,821	30,792
Commitments and Contingencies (Note 9)
Convertible preferred stock:
Convertible preferred stock	0	199,540
Stockholders’ equity (deficit):
Preferred stock, par value $0.0001 per share—500,000 shares authorized, none issued and outstanding	0	0
Common stock, par value $0.0001 per share—500,000,000 shares and 58,669,600 shares authorized at September 28, 2019 and December 31, 2018, respectively; 60,565,840 and 6,951,350 shares issued and outstanding at September 28, 2019 and December 31, 2018, respectively	6	1
Additional paid-in capital	518,485	7,921
Accumulated deficit	(141,663)	(129,672)
Total stockholders’ equity (deficit)	376,828	(121,750)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	454,841	133,749
Series A
Convertible preferred stock:
Convertible preferred stock	0	2,000
Series B
Convertible preferred stock:
Convertible preferred stock	0	4,999
Series C
Convertible preferred stock:
Convertible preferred stock	0	14,882
Series D
Convertible preferred stock:
Convertible preferred stock	0	24,948
Series E
Convertible preferred stock:
Convertible preferred stock	0	17,214
Series F
Convertible preferred stock:
Convertible preferred stock	0	29,840
Series G
Convertible preferred stock:
Convertible preferred stock	0	55,658
Series H
Convertible preferred stock:
Convertible preferred stock	$ 0	$ 49,999

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 28, 2019	Dec. 31, 2018
Convertible preferred stock, par value (in shares)		$ 0.0001
Convertible preferred stock, authorized (in shares)		43,882,867
Convertible preferred stock, outstanding (in shares)	0	41,562,111
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	500,000	500,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	500,000,000	58,669,600
Common stock, issued (in shares)	60,565,840	6,951,350
Common stock, outstanding (in shares)	60,565,840	6,951,350
Series A
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	0	3,333,500
Convertible preferred stock, issued (in shares)	0	3,333,500
Convertible preferred stock, outstanding (in shares)	0	3,333,500
Series B
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	0	4,802,260
Convertible preferred stock, issued (in shares)	0	4,680,565
Convertible preferred stock, outstanding (in shares)	0	4,680,565
Series C
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	0	8,076,643
Convertible preferred stock, issued (in shares)	0	8,076,636
Convertible preferred stock, outstanding (in shares)	0	8,076,636
Series D
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	0	8,713,207
Convertible preferred stock, issued (in shares)	0	8,713,201
Convertible preferred stock, outstanding (in shares)	0	8,713,201
Series E
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	0	4,740,531
Convertible preferred stock, issued (in shares)	0	4,701,449
Convertible preferred stock, outstanding (in shares)	0	4,701,449
Series F
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	0	4,866,776
Convertible preferred stock, issued (in shares)	0	4,866,758
Convertible preferred stock, outstanding (in shares)	0	4,866,758
Series G
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	0	5,140,257
Convertible preferred stock, issued (in shares)	0	5,114,786
Convertible preferred stock, outstanding (in shares)	0	5,114,786
Series H
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	0	4,209,693
Convertible preferred stock, issued (in shares)	0	2,075,216
Convertible preferred stock, outstanding (in shares)	0	2,075,216

Condensed Statements of Operati

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
Income Statement [Abstract]
Net revenues	$ 91,961	$ 26,277	$ 199,418	$ 56,420
Cost of goods sold	59,178	21,235	133,123	46,709
Gross profit	32,783	5,042	66,295	9,711
Research and development expenses	5,951	2,165	14,661	6,267
Selling, general and administrative expenses	20,944	10,353	47,636	23,133
Restructuring expenses	2,319	528	3,560	1,170
Total operating expenses	29,214	13,046	65,857	30,570
Income (loss) from operations	3,569	(8,004)	438	(20,859)
Other income (expense), net:
Interest expense	(855)	(313)	(2,329)	(388)
Remeasurement of warrant liability	0	(994)	(12,503)	(1,253)
Other income (expense), net	1,385	(31)	2,424	66
Total other income (expense), net	530	(1,338)	(12,408)	(1,575)
Income (loss) before taxes	4,099	(9,342)	(11,970)	(22,434)
Income tax expense	0	0	21	0
Net income (loss)	$ 4,099	$ (9,342)	$ (11,991)	$ (22,434)
Net income (loss) per share available to common stockholders—basic (in dollars per share)	$ 0.07	$ (1.45)	$ (0.33)	$ (3.68)
Weighted average common shares outstanding—basic	60,415,866	6,441,838	35,806,520	6,103,756
Net income (loss) per share available to common stockholders—diluted (in dollars per share)	$ 0.06	$ (1.45)	$ (0.33)	$ (3.68)
Weighted average common shares outstanding—diluted	66,026,490	6,441,838	35,806,520	6,103,756

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Loans to Related Parties	Accumulated Deficit	IPO	IPOCommon Stock	IPOAdditional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2017	39,361,211
Beginning balance at Dec. 31, 2017	$ 148,194
Preferred Stock
Issuance of Series G preferred stock, net of issuance costs (in shares)	112,945
Issuance of Series G preferred stock, net of issuance costs	$ 1,228
Ending balance (in shares) at Mar. 31, 2018	39,474,156
Ending balance at Mar. 31, 2018	$ 149,422
Beginning balance (in shares) at Dec. 31, 2017		5,724,506
Beginning balance at Dec. 31, 2017	(95,913)	$ 1	$ 4,823	$ (951)	$ (99,786)
Common Stock
Net income (loss)	(5,696)				(5,696)
Issuance of common stock through equity incentive plans (in shares)		92,310
Issuance of common stock through equity incentive plans	88		88
Share-based compensation	260		260
Issuance of Series G preferred stock, net of issuance costs	0
Ending balance (in shares) at Mar. 31, 2018		5,816,816
Ending balance at Mar. 31, 2018	$ (101,261)	$ 1	5,171	(951)	(105,482)
Beginning balance (in shares) at Dec. 31, 2017	39,361,211
Beginning balance at Dec. 31, 2017	$ 148,194
Ending balance (in shares) at Sep. 29, 2018	39,486,895
Ending balance at Sep. 29, 2018	$ 149,541
Beginning balance (in shares) at Dec. 31, 2017		5,724,506
Beginning balance at Dec. 31, 2017	(95,913)	$ 1	4,823	(951)	(99,786)
Common Stock
Net income (loss)	(22,434)
Issuance of common stock upon conversion of convertible preferred stock	0
Reclassification of warrant liability to additional paid-in capital in connection with the initial public offering	0
Ending balance (in shares) at Sep. 29, 2018		6,616,705
Ending balance at Sep. 29, 2018	$ (115,692)	$ 1	6,527	0	(122,220)
Beginning balance (in shares) at Mar. 31, 2018	39,474,156
Beginning balance at Mar. 31, 2018	$ 149,422
Preferred Stock
Issuance of Series G preferred stock, net of issuance costs (in shares)	12,739
Issuance of Series G preferred stock, net of issuance costs	$ 121
Ending balance (in shares) at Jun. 30, 2018	39,486,895
Ending balance at Jun. 30, 2018	$ 149,543
Beginning balance (in shares) at Mar. 31, 2018		5,816,816
Beginning balance at Mar. 31, 2018	(101,261)	$ 1	5,171	(951)	(105,482)
Common Stock
Net income (loss)	(7,396)				(7,396)
Issuance of common stock through equity incentive plans (in shares)		624,411
Issuance of common stock through equity incentive plans	783		783
Share-based compensation	450		450
Issuance of Series G preferred stock, net of issuance costs	0
Ending balance (in shares) at Jun. 30, 2018		6,441,227
Ending balance at Jun. 30, 2018	(107,424)	$ 1	6,404	(951)	(112,878)
Preferred Stock
Issuance of Series G preferred stock, net of issuance costs	$ (2)
Ending balance (in shares) at Sep. 29, 2018	39,486,895
Ending balance at Sep. 29, 2018	$ 149,541
Common Stock
Net income (loss)	(9,342)				(9,342)
Issuance of common stock through equity incentive plans (in shares)		224,387
Issuance of common stock through equity incentive plans	257		257
Re-purchase of common stock (in shares)		(48,909)
Re-purchase of common stock	(514)		(514)
Share-based compensation	380		380
Issuance of Series G preferred stock, net of issuance costs	0
Payoff of promissory notes receivable for restricted stock purchase	951			951
Ending balance (in shares) at Sep. 29, 2018		6,616,705
Ending balance at Sep. 29, 2018	$ (115,692)	$ 1	6,527	$ 0	(122,220)
Beginning balance (in shares) at Dec. 31, 2018	41,562,111
Beginning balance at Dec. 31, 2018	$ 199,540
Ending balance (in shares) at Mar. 30, 2019	41,562,111
Ending balance at Mar. 30, 2019	$ 199,540
Beginning balance (in shares) at Dec. 31, 2018		6,951,350
Beginning balance at Dec. 31, 2018	(121,750)	$ 1	7,921		(129,672)
Common Stock
Net income (loss)	(6,649)				(6,649)
Issuance of common stock through equity incentive plans (in shares)		169,583
Issuance of common stock through equity incentive plans	366		366
Share-based compensation	855		855
Ending balance (in shares) at Mar. 30, 2019		7,120,933
Ending balance at Mar. 30, 2019	$ (127,178)	$ 1	9,142		(136,321)
Beginning balance (in shares) at Dec. 31, 2018	41,562,111
Beginning balance at Dec. 31, 2018	$ 199,540
Ending balance (in shares) at Sep. 28, 2019	0
Ending balance at Sep. 28, 2019	$ 0
Beginning balance (in shares) at Dec. 31, 2018		6,951,350
Beginning balance at Dec. 31, 2018	(121,750)	$ 1	7,921		(129,672)
Common Stock
Net income (loss)	(11,991)
Issuance of common stock upon conversion of convertible preferred stock	199,540
Reclassification of warrant liability to additional paid-in capital in connection with the initial public offering	14,421
Ending balance (in shares) at Sep. 28, 2019		60,565,840
Ending balance at Sep. 28, 2019	$ 376,828	$ 6	518,485		(141,663)
Beginning balance (in shares) at Mar. 30, 2019	41,562,111
Beginning balance at Mar. 30, 2019	$ 199,540
Preferred Stock
Issuance of common stock upon conversion of convertible preferred stock (in shares)	(41,562,111)
Issuance of common stock upon conversion of convertible preferred stock	$ (199,540)
Ending balance (in shares) at Jun. 29, 2019	0
Ending balance at Jun. 29, 2019	$ 0
Beginning balance (in shares) at Mar. 30, 2019		7,120,933
Beginning balance at Mar. 30, 2019	(127,178)	$ 1	9,142		(136,321)
Common Stock
Net income (loss)	(9,441)				(9,441)
Issuance of common stock upon conversion of convertible preferred stock (in shares)		41,562,111					11,068,750
Issuance of common stock upon conversion of convertible preferred stock	199,540	$ 4	199,536			$ 252,453	$ 1	$ 252,452
Issuance of common stock upon exercise of common stock warrants (in shares)		214,875
Issuance of common stock upon exercise of common stock warrants	0
Reclassification of warrant liability to additional paid-in capital in connection with the initial public offering	14,421		14,421
Issuance of common stock through equity incentive plans (in shares)		200,852
Issuance of common stock through equity incentive plans	167		167
Share-based compensation	1,823		1,823
Ending balance (in shares) at Jun. 29, 2019		60,167,521
Ending balance at Jun. 29, 2019	$ 331,785	$ 6	477,541		(145,762)
Ending balance (in shares) at Sep. 28, 2019	0
Ending balance at Sep. 28, 2019	$ 0
Common Stock
Net income (loss)	4,099				4,099
Issuance of common stock upon conversion of convertible preferred stock (in shares)							250,000
Issuance of common stock upon conversion of convertible preferred stock						$ 37,450		37,450
Issuance of common stock through equity incentive plans (in shares)		148,319
Issuance of common stock through equity incentive plans	365		365
Share-based compensation	3,129							$ 3,129
Ending balance (in shares) at Sep. 28, 2019		60,565,840
Ending balance at Sep. 28, 2019	$ 376,828	$ 6	$ 518,485		$ (141,663)

Condensed Statements of Conve_2

Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Statement of Stockholders' Equity [Abstract]
Issuance costs, preferred stock	$ 19	$ 7

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018
Cash flows from operating activities:
Net loss	$ (11,991)	$ (22,434)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,980	3,046
Share-based compensation expense	5,807	1,090
Loss on sale of fixed assets	0	76
Amortization of debt issuance costs	124	51
Change in preferred and common stock warrant liabilities	12,503	1,253
Net change in operating assets and liabilities:
Accounts receivable	(21,856)	(8,499)
Inventories	(30,013)	(9,627)
Prepaid expenses and other assets	(1,878)	(615)
Accounts payable	20,206	7,670
Accrued expenses and other current liabilities	2,768	3,573
Long-term liabilities	11	39
Net cash used in operating activities	(18,339)	(24,377)
Cash flows used in investing activities:
Purchases of property, plant and equipment	(9,515)	(18,250)
Proceeds from sale of fixed assets	307	104
Purchases of property, plant and equipment held for sale	(7,403)	0
Payment of security deposits	(542)	(59)
Net cash used in investing activities	(17,153)	(18,205)
Cash flows from financing activities:
Proceeds from issuance of common stock pursuant to the initial public offering, net of issuance costs	254,868	0
Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance costs	37,937	0
Proceeds from advance deposit for Series H preferred stock offering	0	25,000
Proceeds from Series G preferred stock offering, net of offering costs	0	1,347
Proceeds from bank term loan borrowing	0	20,000
Repayments on revolving credit line	0	(2,500)
Repayment on term loan	0	(1,000)
Proceeds from payoff of notes receivable for restricted stock purchase	0	951
Proceeds from revolving credit line	0	6,000
Proceeds from equipment loan borrowing	0	5,000
Repayment of Missouri Note	0	(1,450)
Payments of capital lease obligations	(31)	(143)
Proceeds from exercise of stock options	898	1,128
Payments of deferred offering costs	0	(492)
Payment for repurchase of common stock	0	(514)
Net cash provided by financing activities	293,672	53,327
Net increase in cash and cash equivalents	258,180	10,745
Cash and cash equivalents at the beginning of the period	54,271	39,035
Cash and cash equivalents at the end of the period	312,451	49,780
Cash paid during the period for:
Interest	2,261	356
Taxes	21	3
Non-cash investing and financing activities:
Capital lease obligations for the purchase of property, plant and equipment	0	85
Issuance of convertible preferred stock warrants in connection with debt	0	248
Non-cash additions to property, plant and equipment	1,280	730
Offering costs, accrued not yet paid	487	1,301
Non-cash additions to property, plant and equipment held for sale	1,019	0
Reclassification of warrant liability to additional paid-in capital in connection with the initial public offering	14,421	0
Conversion of convertible preferred stock to common stock upon initial public offering	$ 199,540	$ 0

Introduction

Introduction	9 Months Ended
	Sep. 28, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Introduction	Introduction The Company Beyond Meat, Inc., a Delaware corporation (the “Company”), is one of the fastest growing food companies in the United States, offering a portfolio of revolutionary plant-based meats. The Company builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating the Company’s plant-based meat products. The Company’s brand commitment, “Eat What You Love,” represents a strong belief that by eating the Company’s plant-based meats, consumers can enjoy more, not less, of their favorite meals, and by doing so, help address concerns related to human health, climate change, resource conservation and animal welfare. The Company’s primary production facilities are located in Columbia, Missouri, and research and development and administrative offices are located in El Segundo, California. In addition to its own production facilities, the Company uses co-manufacturers in various locations in the United States to manufacture its products. In May 2019, the Company partnered with one of its distributors to co-manufacture the Company’s products at a new manufacturing facility being constructed by this distributor in the Netherlands for estimated completion in 2020. The Company sells to a variety of customers in the retail and foodservice channels throughout the United States and internationally through brokers and distributors. All of the Company’s long-lived assets are located in the United States. Initial Public Offering On May 6, 2019, the Company completed its initial public offering (“IPO”) of common stock, in which it sold 11,068,750 shares, including 1,443,750 shares pursuant to the underwriters’ over-allotment option. The shares began trading on the Nasdaq Global Select Market on May 2, 2019. The shares were sold at an IPO price of $25.00 per share for net proceeds of approximately $252.4 million , after deducting underwriting discounts and commissions of $19.4 million and offering expenses of approximately $4.9 million payable by the Company. Upon the closing of the IPO, all outstanding shares of the Company’s convertible preferred stock automatically converted into 41,562,111 shares of common stock on a one -for-one basis, and warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 160,767 shares of common stock. Secondary Public Offering On August 5, 2019, the Company completed a secondary public offering (“Secondary Offering”) of common stock, in which it sold 250,000 shares and the selling stockholders sold 3,487,500 shares, including 487,500 shares pursuant to the underwriters’ over-allotment option. The shares were sold at a price of $160.00 per share for net proceeds to the Company of approximately $37.5 million , after deducting underwriting discounts and commissions of $1.5 million and offering expenses of approximately $1.0 million payable by the Company. The Company

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 28, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“ SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the condensed financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2019 or for any other interim period or for any other future fiscal year. These condensed financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the prospectus dated May 1, 2019 filed with the SEC on May 3, 2019 (the “Prospectus”) . The condensed balance sheet as of December 31, 2018 has been derived from the audited financial statements at that date. There have been no material changes in the Company’s significant accounting policies from those that were disclosed in the Prospectus, except as noted below. Fiscal Year The Company operates on a fiscal calendar year, and each interim quarter is comprised of one 5-week period and two 4-week periods, with each week ending on a Saturday. The Company’s fiscal year always begins on January 1 and ends on December 31. As a result, the Company’s first and fourth fiscal quarters may have more or fewer days included than a traditional 91 -day fiscal quarter. Management’s Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates made by the Company include trade promotion accruals; useful lives of property, plant and equipment; valuation of deferred tax assets; valuation of inventory; and the valuation of the fair value of common stock and preferred stock used to determine stock compensation expense and in the remeasurement of warrants and liabilities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates and such differences may be material to the condensed financial statements. Reverse Stock Split On January 2, 2019, the Company effected a 3 -to- 2 reverse stock split of its outstanding common stock and convertible preferred stock, including outstanding stock options and common and convertible preferred stock warrants. The reverse stock split did not result in an adjustment to par value. All references in the accompanying condensed financial statements and related notes to the number of shares of common stock, convertible preferred stock, warrants and options to purchase common stock and per share data reflect the effect of the reverse stock split. Cash and Cash Equivalents The Company maintains cash balances at one financial institution in the United States. The cash balances may, at times, exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation or FDIC up to $250,000 . The Company considers all highly liquid investments with original maturity dates of 90 days or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts . Deferred Offering Costs Offering costs, consisting primarily of legal, accounting, printing and filing services, and other direct fees and costs related to the IPO, were capitalized and offset against proceeds upon the consummation of the IPO. Total IPO issuance costs were $4.9 million , of which $2.4 million was incurred and paid as of December 31, 2018 and an additional $2.5 million was incurred and paid during the nine months ended September 28, 2019 . There were no unpaid IPO issuance costs in accounts payable as of September 28, 2019 . Stock Warrant Liability The Company accounts for freestanding warrants to purchase shares of its convertible preferred stock or common stock as a liability, as the underlying shares of convertible preferred stock and common stock are contingently redeemable and, therefore, may obligate the Company to transfer assets at some point in the future. The warrants were recorded at fair value upon issuance and are subject to remeasurement at each balance sheet date. Any change in fair value is recognized in the condensed statements of operations in Total other income (expense), net. Prior to the IPO, the Company had outstanding warrants to purchase an aggregate of 60,002 shares of its common stock at an exercise price of $3.00 per share, 121,694 shares of its Series B convertible preferred stock at an exercise price of $1.07 per share and 39,073 shares of its Series E convertible preferred stock at an exercise price of $3.68 per share. On May 6, 2019, in connection with the IPO, the warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 160,767 shares of common stock at the same respective exercise price per share. Subsequent to the closing of the IPO, all outstanding warrants to purchase shares of common stock were cashless exercised. Fair Value of Financial Instruments The fair value measurement accounting guidance creates a fair value hierarchy to prioritize the inputs used to measure fair value into three categories. A financial instrument’s level within the fair value hierarchy is based on the lowest level of input significant to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. The three levels are defined as follows: • Level 1 —Unadjusted quoted prices in active markets accessible by the reporting entity for identical assets or liabilities. Active markets are those in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. • Level 2 —Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which significant value drivers are observable. • Level 3 —Valuations derived from valuation techniques in which significant value drivers are unobservable. The Company’s financial instruments include cash equivalents, accounts receivable, accounts payable, and accrued expenses, for which the carrying amounts approximate fair value due to the short-term maturity of these financial instruments. Based on the borrowing rates currently available to the Company for debt with similar terms, the carrying value of the line of credit, term debt with its bank, and equipment loan approximate fair value as well. The Company had no financial instruments measured at fair value on a recurring basis as of September 28, 2019 . Prior to the IPO, the stock warrant liability was measured at fair value using Level 3 inputs upon issuance and at each reporting date. Inputs used to determine the estimated fair value of the warrant liability as of the valuation date included expected term of the warrants, the risk-free interest rate, volatility, and the fair value of underlying shares. The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis based on the fair value hierarchy as of December 31, 2018 (in thousands): December 31, 2018 Level 1 Level 2 Level 3 Total Financial Liabilities: Preferred stock warrant liability $ — $ — $ 1,441 $ 1,441 Common stock warrant liability — — 477 477 Total $ — $ — $ 1,918 $ 1,918 The following table sets forth a summary of the changes in the fair value of the preferred and common stock warrant liabilities: For the Nine Months Ended (in thousands) September 28, 2019 September 29, 2018 Beginning balance $ 1,918 $ 550 Fair value of warrants issued during the period — 248 Change in fair value of warrant liability 12,503 1,253 Reclassification of warrant liability to additional paid-in capital in connection with the IPO (14,421 ) — Ending balance $ — $ 2,051 The Company remeasured and reclassified the common stock warrant liability to additional paid-in-capital in connection with the IPO. Subsequent to the closing of the IPO, all outstanding warrants to purchase shares of common stock were cashless exercised and no warrants were outstanding as of September 28, 2019 . Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which, along with subsequent ASUs, amends the existing accounting standards for revenue recognition (“Topic 606”). This guidance is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to receive when products are transferred to customers. ASU 2014-09 was effective for the Company beginning January 1, 2019. The majority of the Company’s contracts with customers generally consist of a single performance obligation to transfer promised goods. Based on the Company’s evaluation process and review of its contracts with customers, the timing and amount of revenue recognized based on ASU 2014-09 is consistent with the Company’s revenue recognition policy under previous guidance. The Company has therefore concluded that the adoption of ASU 2014-09 did not have a material impact on its financial position, results of operations, or cash flows. Revenue is recognized at the point in which the performance obligation under the terms of a contract with the customer have been satisfied and control has transferred. The Company’s performance obligation is typically defined as the accepted purchase order, or the contract, with the customer which requires the Company to deliver the requested products at agreed upon prices at the time and location of the customer’s choice. The Company does not offer warranties or a right to return on the products it sells except in the instance of a product recall. Revenue is measured as the amount of consideration the Company expects to receive in exchange for fulfilling the performance obligation. Sales and other taxes the Company collects concurrent with the sale of products are excluded from revenue. The Company's normal payment terms vary by the type and location of its customers and the products offered. The time between invoicing and when payment is due is not significant. None of the Company's customer contracts as of September 28, 2019 contains a significant financing component. The Company routinely offers sales discounts and promotions through various programs to its customers and consumers. These programs include rebates, temporary on shelf price reductions, off invoice discounts, retailer advertisements, and other trade activities. Provision for discounts and incentives are recorded in the same period in which the related revenues are recognized. At the end of each accounting period, the Company recognizes a liability for estimated sales discounts that have been incurred but not paid which totaled $2.2 million and $0.8 million as of September 28, 2019 and December 31, 2018 , respectively. The offsetting charge is recorded as a reduction of revenues in the same period when the expense is incurred. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental cost to obtain contracts was not material . The Company’s net revenues by platform and channel are included in the tables below: For the Three Months Ended For the Nine Months Ended (in thousands) September 28, September 29, September 28, September 29, Net revenues: Gross Fresh Platform $ 97,995 $ 26,815 $ 204,523 $ 51,530 Gross Frozen Platform 4,007 2,295 14,158 11,549 Less: Discounts (10,041 ) (2,833 ) (19,263 ) (6,659 ) Net revenues $ 91,961 $ 26,277 $ 199,418 $ 56,420 For the Three Months Ended For the Nine Months Ended (in thousands) September 28, September 29, September 28, September 29, Net revenues: Retail $ 50,465 $ 16,201 $ 104,164 $ 37,173 Restaurant and Foodservice 41,496 10,076 95,254 19,247 Net revenues $ 91,961 $ 26,277 $ 199,418 $ 56,420 Two distributors accounted for approximately 17% and 15% , respectively, of the Company’s gross revenues in the three months ended September 28, 2019 ; and three distributors accounted for approximately 39% , 22% and 13% , respectively, of the Company’s gross revenues in the three months ended September 29, 2018 . Two distributors accounted for approximately 19% and 18% , respectively, of the Company’s gross revenues in the nine months ended September 28, 2019 ; and three distributors accounted for approximately 38% , 17% and 14% , respectively, of the Company’s gross revenues in the nine months ended September 29, 2018 . Approximately 14% of the Company’s net revenues in the three months ended September 28, 2019 was from international sales, excluding sales in Canada, as compared to approximately 4% in the three months ended September 29, 2018 . Approximately 12% of the Company’s net revenues in the nine months ended September 28, 2019 was from international sales, excluding sales in Canada, as compared to approximately 3% in the nine months ended September 29, 2018 . Net revenues from sales to the Canadian market are included with net revenues from sales to the United States market. Shipping and Handling Costs Outbound shipping and handling costs included in selling, general and administrative (“SG&A”) expenses in the three months ended September 28, 2019 and September 29, 2018 were $3.4 million and $2.1 million , respectively, and in the nine months ended September 28, 2019 and September 29, 2018 were $7.4 million and $4.9 million , respectively. Earnings (Loss) Per Share Earnings (loss) per share (“EPS”) represents net income available to common stockholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS represents net income available to common stockholders divided by the weighted-average number of common shares outstanding, inclusive of the dilutive impact of potential common shares outstanding during the period. Such potential common shares include options, unvested restricted stock, restricted stock units (“RSUs”), warrants and convertible preferred stock. The Company calculates basic and diluted EPS available to common stockholders in conformity with the two-class method required for companies with participating securities. The Company considers all series of convertible preferred stock issued and outstanding prior to the IPO to be participating securities. Under the two-class method, the net loss available to common stockholders is not allocated to the convertible preferred stock as the holders of convertible preferred stock issued and outstanding prior to the IPO did not have a contractual obligation to share in losses. N onvested restricted stock awards (referred to as participating securities) are excluded from the dilutive impact of common equivalent shares outstanding in accordance with authoritative guidance under the two-class method. The nonvested restricted stockholders are entitled to participate in dividends declared on common stock as if the shares were fully vested and hence nonvested restricted stock shares are deemed to be participating securities. Under the two-class method, net income, but not net loss, available to nonvested restricted stockholders is excluded from net income available to common stockholders for purposes of calculating basic and diluted EPS. N et loss available to common stockholders is not allocated to unvested restricted stock as the holders of unvested restricted stock do not have a contractual obligation to share in losses. In periods when the Company records net loss, all potential common shares are excluded in the computation of EPS because their inclusion would be anti-dilutive. See Note 11 . Related-Party Transactions Seth Goldman The Company entered into a consulting agreement with Seth Goldman, the Company’s Executive Chair, on March 2, 2016, which was amended and restated on November 15, 2018 and further amended on April 8, 2019. Pursuant to the consulting agreement, the Company will pay Mr. Goldman $20,210.33 per month for services rendered under the consulting agreement and, on the date of each annual meeting of the Company’s stockholders after which Mr. Goldman’s non-employee service on the board of directors will continue, the Company has agreed to grant Mr. Goldman a restricted stock unit award under the 2018 Equity Incentive Plan (the “Plan”), having a grant date fair value of $105,000 . Each restricted stock unit grant will vest based on continued service in equal monthly installments over the 12 -month period following the grant date, provided it will vest in full immediately prior to, and contingent upon, a change in control of the Company. The consulting agreement may be terminated by either party at any time upon 120 business days’ written notice. In the event of a default in the performance of the consulting agreement or material breach of any obligations under the consulting agreement, the non-breaching party may terminate the consulting agreement immediately if the breaching party fails to cure the breach within 30 business days after having received written notice by the non-breaching party of the default or breach. Bernhard van Lengerich The Company first entered into an advisor agreement with Food System Strategies, LLC in October 2015. Bernhard van Lengerich. Ph.D., a member of the Company’s Board of Directors, is the Chief Executive Officer of Food System Strategies, LLC. Pursuant to this advisor agreement, the Company paid Food System Strategies, LLC $4,000 for each day Dr. van Lengerich provided services, provided the Company paid Food System Strategies, LLC for at least two days of services per month. In February 2016, the Company entered into a new advisor agreement with Food System Strategies, LLC, which superseded the original agreement and provided for a $25,000 monthly retainer and a non-qualified stock option covering 798,848 shares, which vested in equal monthly installments over three years in consideration of Dr. van Lengerich providing services as the Company’s interim Chief Technical Officer and head of research and development, and the increased time commitment associated with these roles. In December 2016, the advisor agreement was amended to provide for a $10,000 monthly retainer to reflect the fact that Dr. van Lengerich would only be providing advisory services five to six days a month going forward. The advisor agreement may be terminated at any time upon written notice to the other party. Donald Thompson In the nine months ended September 29, 2018 , the Company incurred consulting costs payable to a company associated with Donald Thompson, a member of the Company’s Board of Directors, in the amount of $47,162 . The Company did not incur any such consulting costs in the nine months ended September 28, 2019 . Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). Under ASU 2018-07, the measurement of equity-classified nonemployee awards will be fixed at the grant date, and nonpublic entities are allowed to account for nonemployee awards using certain practical expedients that are already available for employee awards. The amendments in ASU 2018-07 are effective for nonpublic business entities for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than the Company’s adoption date of Topic 606. The Company early adopted ASU 2018-07 beginning January 1, 2019 along with its adoption of ASU 2014-09. Pursuant to ASU 2018-07, the measurement of equity classified nonemployee awards will be fixed at the grant date, as compared to the previous requirement to remeasure the awards through the performance completion date. New Accounting Pronouncements As an “emerging growth company,” the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”), which makes amendments to the guidance in GAAP on the classification and measurement of financial instruments. ASU 2016-01 significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. It also amends certain disclosure requirements associated with the fair value of financial instruments. For all entities other than public entities, ASU 2016-01 is effective for fiscal years beginning after December 15, 2018, including interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company expects to adopt and implement ASU 2016-01 for the year ending December 31, 2019 and for interim periods beginning January 1, 2020. The Company does not expect that adoption of ASU 2016-01 will have a material impact on the Company’s financial position, results of operations, or cash flows.

Restructuring

Restructuring	9 Months Ended
	Sep. 28, 2019
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In May 2017, management approved a plan to terminate the Company’s exclusive supply agreement (the “Agreement”) with one of its co-manufacturers, due to non-performance under the Agreement and on May 23, 2017, the Company notified the co-manufacturer of its decision to terminate the Agreement. In the three months ended September 28, 2019 and September 29, 2018 , the Company recorded $2.3 million and $0.5 million , respectively, in restructuring expenses related to this dispute, which consisted primarily of legal and other expenses. In the nine months ended September 28, 2019 and September 29, 2018 , the Company recorded $3.6 million and $1.2 million , respectively, in restructuring expenses related to this dispute, which consisted primarily of legal and other expenses. See Note 9 for further information. As of September 28, 2019 and December 31, 2018 , the Company had $0.7 million and $0

Inventories

Inventories	9 Months Ended
	Sep. 28, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Major classes of inventory were as follows: (in thousands) September 28, December 31, Raw materials and packaging $ 32,429 $ 13,756 Work in process 4,439 2,517 Finished goods 23,402 13,984 Total $ 60,270 $ 30,257

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 28, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant, and equipment are stated at cost and capital lease assets are included. A summary of property, plant, and equipment as of September 28, 2019 and December 31, 2018 , is as follows: (in thousands) September 28, 2019 December 31, 2018 Manufacturing equipment $ 29,952 $ 25,314 Research and development equipment 7,786 6,088 Leasehold improvements 7,468 7,080 Capital leases 883 882 Software 216 60 Furniture and fixtures 410 195 Vehicles 210 210 Assets not yet placed in service 6,776 3,374 Total property, plant and equipment $ 53,701 $ 43,203 Less: accumulated depreciation and amortization 18,651 12,676 Property, plant and equipment, net $ 35,050 $ 30,527 Depreciation and amortization expense for the three months ended September 28, 2019 and September 29, 2018 , was $2.0 million and $1.4 million , respectively. Of the total depreciation and amortization expense in the three months ended September 28, 2019 and September 29, 2018 , $1.4 million and $1.0 million , respectively, were recorded in cost of goods sold, $0.6 million and $0.4 million , respectively, were recorded in research and development expenses, and $17,000 and $3,000 , respectively, were recorded in SG&A expenses, in the Company’s condensed statements of operations. Depreciation and amortization expense for the nine months ended September 28, 2019 and September 29, 2018 , was $6.0 million and $3.0 million , respectively. Of the total depreciation and amortization expense in the nine months ended September 28, 2019 and September 29, 2018 , $4.2 million and $2.4 million , respectively, were recorded in cost of goods sold, $1.8 million and $0.6 million , respectively, were recorded in research and development expenses, and $39,000 and $3,000 , respectively, were recorded in SG&A expenses, in the Company’s condensed statements of operations. The Company has $8.9 million and $1.0 million in property, plant and equipment concluded to meet the criteria for assets held for sale in prepaid expenses and other current assets on the condensed balance sheets as of September 28, 2019 and December 31, 2018 , respectively. The Company expects to sell such assets in 2019 for amounts that approximate book value.

Debt

Debt	9 Months Ended
	Sep. 28, 2019
Debt Disclosure [Abstract]
Debt	Debt The Company’s debt balances are detailed below: (in thousands) September 28, 2019 December 31, 2018 2018 Revolving Credit Facility (defined below) $ 6,000 $ 6,000 2018 Term Loan Facility (defined below) 20,000 20,000 Equipment financing loan 5,000 5,000 Debt issuance costs (488 ) (612 ) Total debt outstanding $ 30,512 $ 30,388 Less: current portion of long-term debt 9,087 — Long-term debt $ 21,425 $ 30,388 The Company records debt issuance costs as a reduction of carrying value of the debt in the accompanying condensed balance sheets. Debt issuance costs, net of amortization, totaled $0.5 million and $0.6 million as of September 28, 2019 and December 31, 2018 , respectively. Debt issuance costs are amortized as interest expense over the term of the loan for which amortization of $46,000 and $16,000 was recorded during the three months ended September 28, 2019 and September 29, 2018 , respectively, and $124,000 and $51,000 was recorded during the nine months ended September 28, 2019 and September 29, 2018 , respectively. Amended and Restated Loan and Security Agreement In June 2018, the Company refinanced its then existing revolving credit facility and term loan facility under a loan and security agreement with Silicon Valley Bank (“SVB”) (the “Amended LSA”). The Amended LSA includes a $6.0 million revolving credit facility (the “2018 Revolving Credit Facility”) and a term loan facility (the “2018 Term Loan Facility”) comprised of (i) a $10.0 million term loan advance at closing, (ii) a conditional $5.0 million term loan advance, if no event of default has occurred and is continuing through the borrowing date, and (iii) an additional conditional term loan advance of $5.0 million if no event of default has occurred and is continuing based upon a minimum level of gross profit for the trailing 12 -month period. The 2018 Term Loan Facility has a floating interest rate that is equal to 4.0% above the prime rate, with interest payable monthly and principal amortizing commencing on January 1, 2020, and will mature in June 2022. Borrowings under the 2018 Revolving Credit Facility carry a variable annual interest rate of prime rate plus 0.75% to 1.25% with an additional 5% on the outstanding balances in the event of a default. The 2018 Revolving Credit Facility matures in June 2020. The 2018 Term Loan Facility and the 2018 Revolving Credit Facility (the “SVB Credit Facilities,”) contain customary negative covenants that limit the Company’s ability to, among other things, incur additional indebtedness, grant liens, make investments, repurchase stock, pay dividends, transfer assets and merge or consolidate. The SVB Credit Facilities are secured by a blanket lien on all of the Company’s personal property assets. The SVB Credit Facilities also contain customary affirmative covenants, including delivery of audited financial statements. The Company was in compliance with the covenants in the SVB Credit Facilities as of September 28, 2019 . As of September 28, 2019 and December 31, 2018 , the Company had $6.0 million and $20.0 million in borrowings on the 2018 Revolving Credit Facility and 2018 Term Loan Facility, respectively, and had no availability to borrow under either of these loan facilities. In the three months ended September 28, 2019 and September 29, 2018 , the Company incurred $0.7 million and $0.3 million , respectively, in interest expense related to the SVB credit facilities. In the nine months ended September 28, 2019 and September 29, 2018 , the Company incurred $1.9 million and $0.3 million , respectively, in interest expense related to the SVB credit facilities. The interest rates on the 2018 Revolving Credit Facility and the 2018 Term Loan Facility at September 28, 2019 were 6.00% and 9.00% , respectively. Equipment Loan Facility The Company had $5.0 million in borrowings outstanding as of September 28, 2019 and December 31, 2018 under the equipment loan facility. The interest rate on the equipment loan facility at September 28, 2019 and December 31, 2018 was 11.25% and 11.5% , respectively. For the three months ended September 28, 2019 and September 29, 2018 , the Company recorded $0.1 million and $19,000 , respectively, in interest expense related to the equipment loan facility. For the nine months ended September 28, 2019 and September 29, 2018 , the Company recorded $0.4 million and $19,000 , respectively, in interest expense related to the equipment loan facility. The Company was in compliance with the covenants contained in the equipment loan facility as of September 28, 2019. Warrant Liabilities In connection with its financing arrangements, the Company issued warrants to purchase shares of its convertible preferred stock. For one of the financing arrangements, the Company issued warrants to purchase 121,694 shares of Series B convertible preferred stock at an exercise price of $1.07 per share. For a separate financing arrangement, the Company issued warrants to purchase 39,073 shares of Series E convertible preferred stock at an exercise price of $3.68 per share. In connection with the Company’s refinancing of its credit facilities with SVB, the Company issued to SVB and its affiliates warrants to purchase an aggregate of 60,002 shares of its common stock at an exercise price of $3.00 per share. Upon the closing of the IPO, the warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 160,767 shares of common stock at the same respective exercise price per share. Subsequent to the closing of the IPO, all outstanding warrants to purchase shares of common stock were cashless exercised and no warrants were outstanding as of September 28, 2019. See Note 2 for further information on the warrant liabilities.

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) and Convertible Preferred Stock	9 Months Ended
	Sep. 28, 2019
Equity [Abstract]
Stockholders’ Equity (Deficit) and Convertible Preferred Stock	Stockholders’ Equity (Deficit) and Convertible Preferred Stock Upon the closing of the IPO, all outstanding shares of the Company’s convertible preferred stock automatically converted into 41,562,111 shares of common stock on a one -for-one basis. On May 6, 2019, the Company filed an Amended and Restated Certificate of Incorporation authorizing the Company to issue 500,000,000 shares of common stock, $0.0001 par value per share, and 500,000 shares of undesignated preferred stock, $0.0001 par value per share, with rights and preferences determined by the Company’s Board of Directors at the time of issuance of such shares. On August 5, 2019, the Company completed its Secondary Offering of common stock, in which it sold 250,000 shares. As of September 28, 2019 , the Company had 60,565,840 shares of common stock issued and outstanding. As of December 31, 2018 , the Company’s shares consisted of 58,669,600 authorized shares of common stock, par value $0.0001 per share, of which 6,951,350 shares were issued and outstanding, and 43,882,867 authorized shares of preferred stock, par value $0.0001 per share, of which 3,333,500 shares of Series A Preferred Stock, 4,680,565 shares of Series B Preferred Stock, 8,076,636 shares of Series C Preferred Stock, 8,713,201 shares of Series D Preferred Stock, 4,701,449 shares of Series E Preferred Stock, 4,866,758 shares of Series F Preferred Stock, 5,114,786 shares of Series G Preferred Stock and 2,075,216 shares of Series H Preferred Stock were issued and outstanding. The Company has not declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 28, 2019
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation On April 11, 2011, the Company’s stockholders approved the 2011 Equity Incentive Plan (“2011 Plan”), and most recently amended the 2011 Plan on April 10, 2019. The 2011 Plan was amended, restated and re-named the 2018 Equity Incentive Plan (“2018 Plan”), which became effective as of April 30, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The remaining shares available for issuance under the 2011 Plan were added to the shares reserved for issuance under the 2018 Plan. The 2018 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to the Company’s employees, directors, and consultants. The maximum aggregate number of shares that may be issued under the 2018 Plan is 14,482,356 shares of the Company’s common stock. In addition, the number of shares reserved for issuance under the 2018 Plan will be increased automatically on the first day of each fiscal year beginning with the 2020 fiscal year, by a number equal to the least of: (i) 2,144,521 shares; (ii) 4.0% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such number of shares determined by the Company’s Board of Directors. The 2018 Plan may be amended, suspended or terminated by the Company’s Board of Directors at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the 2018 Plan as required by applicable law or listing requirements. Unless sooner terminated by the Company’s Board of Directors, the 2018 Plan will automatically terminate on November 14, 2028. The following grants were made pursuant to the 2018 Plan in the nine months ended September 28, 2019 : (i) options to purchase 264,033 shares of common stock were granted to certain employees on April 3, 2019, having an exercise price of $20.02 per share, (ii) options to purchase (A) 1,000,000 shares of common stock were granted to executive officers on April 18, 2019, (B) 48,999 shares of common stock were granted to certain employees on April 29, 2019, and (C) 50,000 shares of common stock were granted to certain executive officers on May 1, 2019, in each case to be effective upon and subject to the effectiveness of the registration statement relating to the Company’s IPO and having an exercise price equal to the IPO price of $25.00 per share, (iii) awards covering 99,433 shares of restricted stock were granted to nonemployees on April 18, 2019 at a purchase price of $0.01 per share to be issued upon payment of the purchase price, (iv) an option to purchase 125,000 shares of common stock was granted to an executive officer on June 10, 2019, having an exercise price of $168.10 per share, (v) 70,360 RSUs with a grant date fair value of $168.10 were granted to certain employees on June 10, 2019, (vi) an option to purchase 5,073 shares of common stock was granted to an executive officer on August 1, 2019, having an exercise price of $176.04 per share, and (vii) 14,862 RSUs with a grant date fair value of $176.04 were granted to certain employees and a consultant on August 1, 2019. As of September 28, 2019 and December 31, 2018 , there were 6,087,169 and 5,120,293 shares, respectively, issuable under stock options outstanding, 85,121 and 0 shares, respectively, issuable under unvested RSUs outstanding, 4,854,085 and 4,335,331 shares, respectively, issued for stock option exercises, RSU settlement, and restricted stock grants, and 3,455,930 and 6,859 shares, respectively, available for grants under the 2018 Plan. Stock Options Option grants in the nine months ended September 28, 2019 generally vest 25% of the total award on the first anniversary of the vesting commencement date, and thereafter ratably vesting monthly over the remaining three-year period. The stock option grant to an executive officer on August 1, 2019 vests monthly over a 48-month period. The following table summarizes the Company’s stock option activity during the nine months ended September 28, 2019 : Number Weighted Weighted Aggregate Intrinsic Value (in thousands) (1) Outstanding at December 31, 2018 5,120,293 $ 3.13 7.3 $ 81,371 Granted 1,493,105 $ 36.61 — $ — Exercised (442,604 ) $ 2.06 — $ 33,440 Cancelled/Forfeited (83,625 ) $ 8.67 — $ — Outstanding at September 28, 2019 6,087,169 $ 11.34 7.3 $ 838,191 Vested and exercisable at September 28, 2019 3,233,150 $ 1.72 5.7 $ 474,955 Vested and expected to vest at September 28, 2019 4,503,505 $ 6.27 6.6 $ 641,908 __________ (1) Aggregate intrinsic value is calculated as the difference between the value of common stock on the transaction date and the exercise price multiplied by the number of shares issuable under the stock option. During the three months ended September 28, 2019 and September 29, 2018 , the Company recorded in aggregate $2.0 million and $0.3 million , respectively, of share-based compensation expense related to options issued to employees and nonemployees. During the nine months ended September 28, 2019 and September 29, 2018 , the Company recorded in aggregate $3.8 million and $1.0 million , respectively, of share-based compensation expense related to options issued to employees and nonemployees. The share-based compensation expense is included in cost of goods sold and SG&A expenses in the Company’s condensed statements of operations. As of September 28, 2019 , there was $9.8 million in unrecognized compensation expense related to nonvested stock option awards which is expected to be recognized over 3.3 years . Restricted Stock Units RSU grants in the nine months ended September 28, 2019 generally vest 25% of the total award on the first anniversary of the grant date, and thereafter ratably vesting quarterly over the remaining three years of the award. The RSU grant to an executive officer on August 1, 2019 vests quarterly over 16 quarters. The RSU grant to a consultant on August 1, 2019 vests monthly over a 12-month period. The following table summarizes the Company’s RSU activity during the nine months ended September 28, 2019 : Number of Shares Weighted Unvested at January 1, 2019 — $ — Granted 85,222 $ 169.48 Vested (101 ) $ 176.04 Unvested at September 28, 2019 85,121 $ 169.49 During the three months ended September 28, 2019 and September 29, 2018 , the Company recorded in aggregate $0.6 million and $0 , respectively, of share-based compensation expense related to RSUs granted to employees and a consultant. During the nine months ended September 28, 2019 and September 29, 2018 , the Company recorded in aggregate $0.7 million and $0 , respectively, of share-based compensation expense related to RSUs granted to employees and a consultant. The share-based compensation expense is included in cost of goods sold and SG&A expenses in the Company’s condensed statements of operations. As of September 28, 2019 , there was $3.8 million in unrecognized compensation expense related to nonvested RSUs which is expected to be recognized over 3.6 years . Restricted Stock to Nonemployees In April 2019, the Company’s Board of Directors approved the issuance of 99,433 shares of restricted stock with a fair value of $20.02 per share and a purchase price of $0.01 per share to nonemployees serving as the Company’s brand ambassadors. The Company has the right to repurchase the unvested shares upon a voluntary or involuntary termination of a brand ambassador’s service; however, as shares vest monthly over 24 months , they are being released from the repurchase option (and all such shares will be released from the repurchase option by May 18, 2021). In October 2018, the Company’s Board of Directors approved the issuance of 135,791 shares of restricted stock with a fair value of $17.03 per share and a purchase price of $0.02 per share to nonemployees serving as the Company’s brand ambassadors. The Company has the right to repurchase the unvested shares upon a voluntary or involuntary termination of a brand ambassador’s service; however, as shares vest monthly over 12 to 24 months , they are being released from the repurchase option (and all such shares will be released from the repurchase option by November 1, 2020). The following table summarizes the Company’s restricted stock activity during the nine months ended September 28, 2019 : Number Weighted Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2018 100,127 1.6 $ 17.03 Granted 99,433 — $ 20.02 Vested/Released (62,626 ) — $ 19.21 Cancelled/Forfeited (23,333 ) — $ — Unvested at September 28, 2019 113,601 1.5 $ 19.49 As of September 28, 2019 , 113,601 shares of restricted stock had been purchased by nonemployee brand ambassadors which remained subject to vesting requirements and repurchase pursuant to restricted stock purchase agreements. During the three and nine months ended September 28, 2019 , the Company recorded in aggregate $0.5 million and $1.3 million , respectively, of share-based compensation expense related to restricted stock issued to nonemployee brand ambassadors, which is included in SG&A expenses in the Company’s condensed statements of operations. During the three and nine months ended September 29, 2018 , the Company recorded no share-based compensation expense related to restricted stock issued to nonemployee brand ambassadors. As of September 28, 2019 , there was $2.5 million in unrecognized compensation expense related to nonvested restricted stock, which is expected to be recognized over 1.5 years . Employee Stock Purchase Plan On November 15, 2018, the Company’s Board of Directors adopted its 2018 Employee Stock Purchase Plan (“2018 ESPP”), which was subsequently approved by the Company’s stockholders and became effective on April 30, 2019, the day immediately prior to the effectiveness of the registration statement filed in connection with the IPO. The 2018 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code (the “Code”) for U . S . employees. In addition, the 2018 ESPP authorizes grants of purchase rights that do not comply with Section 423 of the Code under a separate non-423 component for non-U.S. employees and certain non-U.S. service providers. The Company has reserved 804,195 shares of common stock for issuance under the 2018 ESPP. In addition, the number of shares reserved for issuance under the 2018 ESPP will be increased automatically on the first day of each fiscal year for a period of up to ten years , starting with the 2020 fiscal year, by a number equal to the least of: (i) 536,130 shares; (ii) 1% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such lesser number of shares determined by the Company’s Board of Directors. The 2018 ESPP is expected to be implemented through a series of offerings under which participants are granted purchase rights to purchase shares of the Company’s common stock on specified dates during such offerings. The administrator has not yet approved an offering under the 2018 ESPP.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 28, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases Effective March 1, 2019, the Company entered into a lease for its principal executive offices in El Segundo, California, for an initial term of 5 years . The aggregate lease amount for the five-year term is $2.7 million . The future minimum lease payments required under noncancelable lease obligations related to this lease are $2.4 million due through 2023 (approximately $0.5 million annually) and $0.1 million thereafter. Purchase Commitments As of September 28, 2019 , the Company had committed to purchase pea protein inventory totaling $68.0 million , approximately $20 million in the remainder of 2019, $24 million in 2020, and $24 million in 2021. Litigation On May 25, 2017, a former co-manufacturer of the Company filed a complaint against the Company in the Superior Court of the State of California for the County of Los Angeles asserting claims for (1) breach of contract, (2) misappropriation of trade secrets, (3) unfair competition under California Business & Professions Code Section 17200 Et. Seq., (4) money owed and due, (5) declaratory relief, and (6) injunctive relief, each arising out of the Company’s decision to terminate an exclusive agreement dated December 2, 2014 between the Company and the former co-manufacturer, pursuant to its terms (see Note 3 ). The Company denies these claims, filed counter-claims on July 27, 2017, alleging (1) breach of contract, (2) unfair competition under California Business & Professions Code Section 17200 Et. Seq., and (3) conversion, and is in the process of litigating this matter. In October 2018, the former co-manufacturer filed an amended complaint that added one of the Company’s current contract manufacturers as a defendant, principally for claims arising from the current contract manufacturer’s alleged use of the former co-manufacturer’s alleged trade secrets, and for replacing the former co-manufacturer as one of the Company’s current co-manufacturers. T he current co-manufacturer filed an answer denying all of the former co-manufacturer’s claims, and a cross-complaint against Beyond Meat asserting claims of total and partial equitable indemnity, contribution, and repayment. On March 11, 2019, the former co-manufacturer filed a second amended complaint to add claims of fraud and negligent misrepresentation against the Company. On May 30, 2019, the judge denied the Company’s motion to dismiss the fraud and negligent misrepresentation claims, allowing the claims to proceed. On June 19, 2019, the Company filed an answer denying the former co-manufacturer’s claims. A trial date has been set for May 18, 2020. At this time the Company cannot reasonably estimate the potential liability associated with this litigation, but believes the final resolution of this litigation will not have a material adverse effect on its financial position, results of operations, or cash flows. The Company is involved in various legal proceedings, claims, and litigation arising in the ordinary course of business. Based on the facts currently available, the Company does not believe that the disposition of matters that are pending or asserted will have a material effect on its financial statements.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 28, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the nine months ended September 28, 2019 and September 29, 2018 , the Company recorded $21,000 and $0 in income tax expense in its condensed statements of operations. The Company has evaluated the available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the U.S. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against substantially all deferred tax assets. If the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets will be made and the adjustment would have the effect of increasing net income in the period such determination is made. As of September 28, 2019 , the Company does no t have any accrued interest or penalties related to uncertain tax positions. The Company’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. The Company is subject to U.S. federal tax authority and U.S. state tax authority examinations for all years with respect to net operating loss and credit carryforwards.

Net Income (Loss) Per Share Ava

Net Income (Loss) Per Share Available to Common Stockholders	9 Months Ended
	Sep. 28, 2019
Earnings Per Share [Abstract]
Net Income (Loss) Per Share Available to Common Stockholders	Net Income (Loss) Per Share Available to Common Stockholders The Company calculates basic and diluted net income (loss) per share available to common stockholders in conformity with the two-class method required for companies with participating securities. See Note 2 . Computation of EPS for the three months ended September 28, 2019 includes the dilutive effect of 5,608,822 shares, issuable under stock options with exercise prices below the closing price of the Company's common stock on the last trading day of the applicable period and 1,802 RSUs, but excludes the dilutive effect of 411 RSUs because their inclusion would be anti-dilutive. Computation of EPS for the nine months ended September 28, 2019 excludes the dilutive effect of 6,087,169 shares issuable under stock options and 85,121 RSUs, because the Company incurred a net loss and their inclusion would be anti-dilutive. Computation of EPS for the three and nine months ended September 29, 2018 excludes the dilutive effect of 4,807,941 shares issuable under stock options because the Company incurred net losses and their inclusion would have been antidilutive. (in thousands, except share and per share amounts) Three Months Ended Nine Months Ended September 28, September 29, September 28, September 29, Numerator: Undistributed net income (loss) available to common stockholders $ 4,090 $ (9,342 ) $ (11,991 ) $ (22,434 ) Undistributed net income available to nonvested restricted stockholders 9 — — — Net income (loss) available to common stockholders—basic 4,099 (9,342 ) (11,991 ) (22,434 ) Denominator: Weighted average common shares outstanding—basic 60,415,866 6,441,838 35,806,520 6,103,756 Dilutive effect of shares issuable under stock options 5,608,822 — — — Dilutive effect of RSUs 1,802 — — — Weighted average common shares outstanding—diluted 66,026,490 6,441,838 35,806,520 6,103,756 Net income (loss) per common share available to common stockholders—basic $ 0.07 $ (1.45 ) $ (0.33 ) $ (3.68 ) Net income (loss) per common share available to common stockholders—diluted $ 0.06 $ (1.45 ) $ (0.33 ) $ (3.68 )

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 28, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“ SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the condensed financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2019 or for any other interim period or for any other future fiscal year. These condensed financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the prospectus dated May 1, 2019 filed with the SEC on May 3, 2019 (the “Prospectus”) . The condensed balance sheet as of December 31, 2018
Fiscal Year	Fiscal Year The Company operates on a fiscal calendar year, and each interim quarter is comprised of one 5-week period and two 4-week periods, with each week ending on a Saturday. The Company’s fiscal year always begins on January 1 and ends on December 31. As a result, the Company’s first and fourth fiscal quarters may have more or fewer days included than a traditional 91 -day fiscal quarter.
Management’s Use of Estimates	Management’s Use of Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains cash balances at one financial institution in the United States. The cash balances may, at times, exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation or FDIC up to $250,000 . The Company considers all highly liquid investments with original maturity dates of 90 days or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts .
Deferred Offering Costs	Deferred Offering Costs
Stock Warrant Liability	Stock Warrant Liability The Company accounts for freestanding warrants to purchase shares of its convertible preferred stock or common stock as a liability, as the underlying shares of convertible preferred stock and common stock are contingently redeemable and, therefore, may obligate the Company to transfer assets at some point in the future. The warrants were recorded at fair value upon issuance and are subject to remeasurement at each balance sheet date. Any change in fair value is recognized in the condensed statements of operations in Total other income (expense), net.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value measurement accounting guidance creates a fair value hierarchy to prioritize the inputs used to measure fair value into three categories. A financial instrument’s level within the fair value hierarchy is based on the lowest level of input significant to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. The three levels are defined as follows: • Level 1 —Unadjusted quoted prices in active markets accessible by the reporting entity for identical assets or liabilities. Active markets are those in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. • Level 2 —Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which significant value drivers are observable. • Level 3 —Valuations derived from valuation techniques in which significant value drivers are unobservable. The Company’s financial instruments include cash equivalents, accounts receivable, accounts payable, and accrued expenses, for which the carrying amounts approximate fair value due to the short-term maturity of these financial instruments. Based on the borrowing rates currently available to the Company for debt with similar terms, the carrying value of the line of credit, term debt with its bank, and equipment loan approximate fair value as well.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which, along with subsequent ASUs, amends the existing accounting standards for revenue recognition (“Topic 606”). This guidance is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to receive when products are transferred to customers. ASU 2014-09 was effective for the Company beginning January 1, 2019. The majority of the Company’s contracts with customers generally consist of a single performance obligation to transfer promised goods. Based on the Company’s evaluation process and review of its contracts with customers, the timing and amount of revenue recognized based on ASU 2014-09 is consistent with the Company’s revenue recognition policy under previous guidance. The Company has therefore concluded that the adoption of ASU 2014-09 did not have a material impact on its financial position, results of operations, or cash flows. Revenue is recognized at the point in which the performance obligation under the terms of a contract with the customer have been satisfied and control has transferred. The Company’s performance obligation is typically defined as the accepted purchase order, or the contract, with the customer which requires the Company to deliver the requested products at agreed upon prices at the time and location of the customer’s choice. The Company does not offer warranties or a right to return on the products it sells except in the instance of a product recall. Revenue is measured as the amount of consideration the Company expects to receive in exchange for fulfilling the performance obligation. Sales and other taxes the Company collects concurrent with the sale of products are excluded from revenue. The Company's normal payment terms vary by the type and location of its customers and the products offered. The time between invoicing and when payment is due is not significant. None of the Company's customer contracts as of September 28, 2019 contains a significant financing component. The Company routinely offers sales discounts and promotions through various programs to its customers and consumers. These programs include rebates, temporary on shelf price reductions, off invoice discounts, retailer advertisements, and other trade activities. Provision for discounts and incentives are recorded in the same period in which the related revenues are recognized. At the end of each accounting period, the Company recognizes a liability for estimated sales discounts that have been incurred but not paid which totaled $2.2 million and $0.8 million as of September 28, 2019 and December 31, 2018 , respectively. The offsetting charge is recorded as a reduction of revenues in the same period when the expense is incurred. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental cost to obtain contracts was not material .
Earnings (Loss) Per Share	Earnings (Loss) Per Share Earnings (loss) per share (“EPS”) represents net income available to common stockholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS represents net income available to common stockholders divided by the weighted-average number of common shares outstanding, inclusive of the dilutive impact of potential common shares outstanding during the period. Such potential common shares include options, unvested restricted stock, restricted stock units (“RSUs”), warrants and convertible preferred stock. The Company calculates basic and diluted EPS available to common stockholders in conformity with the two-class method required for companies with participating securities. The Company considers all series of convertible preferred stock issued and outstanding prior to the IPO to be participating securities. Under the two-class method, the net loss available to common stockholders is not allocated to the convertible preferred stock as the holders of convertible preferred stock issued and outstanding prior to the IPO did not have a contractual obligation to share in losses. N onvested restricted stock awards (referred to as participating securities) are excluded from the dilutive impact of common equivalent shares outstanding in accordance with authoritative guidance under the two-class method. The nonvested restricted stockholders are entitled to participate in dividends declared on common stock as if the shares were fully vested and hence nonvested restricted stock shares are deemed to be participating securities. Under the two-class method, net income, but not net loss, available to nonvested restricted stockholders is excluded from net income available to common stockholders for purposes of calculating basic and diluted EPS. N et loss available to common stockholders is not allocated to unvested restricted stock as the holders of unvested restricted stock do not have a contractual obligation to share in losses.
Recently Adopted and New Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). Under ASU 2018-07, the measurement of equity-classified nonemployee awards will be fixed at the grant date, and nonpublic entities are allowed to account for nonemployee awards using certain practical expedients that are already available for employee awards. The amendments in ASU 2018-07 are effective for nonpublic business entities for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than the Company’s adoption date of Topic 606. The Company early adopted ASU 2018-07 beginning January 1, 2019 along with its adoption of ASU 2014-09. Pursuant to ASU 2018-07, the measurement of equity classified nonemployee awards will be fixed at the grant date, as compared to the previous requirement to remeasure the awards through the performance completion date. New Accounting Pronouncements As an “emerging growth company,” the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”), which makes amendments to the guidance in GAAP on the classification and measurement of financial instruments. ASU 2016-01 significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. It also amends certain disclosure requirements associated with the fair value of financial instruments. For all entities other than public entities, ASU 2016-01 is effective for fiscal years beginning after December 15, 2018, including interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company expects to adopt and implement ASU 2016-01 for the year ending December 31, 2019 and for interim periods beginning January 1, 2020. The Company does not expect that adoption of ASU 2016-01 will have a material impact on the Company’s financial position, results of operations, or cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 28, 2019
Accounting Policies [Abstract]
Schedule of financial instruments measured at fair value	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis based on the fair value hierarchy as of December 31, 2018 (in thousands): December 31, 2018 Level 1 Level 2 Level 3 Total Financial Liabilities: Preferred stock warrant liability $ — $ — $ 1,441 $ 1,441 Common stock warrant liability — — 477 477 Total $ — $ — $ 1,918 $ 1,918
Schedule of changes in fair value	The following table sets forth a summary of the changes in the fair value of the preferred and common stock warrant liabilities: For the Nine Months Ended (in thousands) September 28, 2019 September 29, 2018 Beginning balance $ 1,918 $ 550 Fair value of warrants issued during the period — 248 Change in fair value of warrant liability 12,503 1,253 Reclassification of warrant liability to additional paid-in capital in connection with the IPO (14,421 ) — Ending balance $ — $ 2,051
Schedule of net revenues by platform and channel	The Company’s net revenues by platform and channel are included in the tables below: For the Three Months Ended For the Nine Months Ended (in thousands) September 28, September 29, September 28, September 29, Net revenues: Gross Fresh Platform $ 97,995 $ 26,815 $ 204,523 $ 51,530 Gross Frozen Platform 4,007 2,295 14,158 11,549 Less: Discounts (10,041 ) (2,833 ) (19,263 ) (6,659 ) Net revenues $ 91,961 $ 26,277 $ 199,418 $ 56,420 For the Three Months Ended For the Nine Months Ended (in thousands) September 28, September 29, September 28, September 29, Net revenues: Retail $ 50,465 $ 16,201 $ 104,164 $ 37,173 Restaurant and Foodservice 41,496 10,076 95,254 19,247 Net revenues $ 91,961 $ 26,277 $ 199,418 $ 56,420

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 28, 2019
Inventory Disclosure [Abstract]
Schedule of major classes of inventory	Major classes of inventory were as follows: (in thousands) September 28, December 31, Raw materials and packaging $ 32,429 $ 13,756 Work in process 4,439 2,517 Finished goods 23,402 13,984 Total $ 60,270 $ 30,257

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 28, 2019
Property, Plant and Equipment [Abstract]
Schedule of property, plant, and equipment	A summary of property, plant, and equipment as of September 28, 2019 and December 31, 2018 , is as follows: (in thousands) September 28, 2019 December 31, 2018 Manufacturing equipment $ 29,952 $ 25,314 Research and development equipment 7,786 6,088 Leasehold improvements 7,468 7,080 Capital leases 883 882 Software 216 60 Furniture and fixtures 410 195 Vehicles 210 210 Assets not yet placed in service 6,776 3,374 Total property, plant and equipment $ 53,701 $ 43,203 Less: accumulated depreciation and amortization 18,651 12,676 Property, plant and equipment, net $ 35,050 $ 30,527

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 28, 2019
Debt Disclosure [Abstract]
Schedule of debt balances	The Company’s debt balances are detailed below: (in thousands) September 28, 2019 December 31, 2018 2018 Revolving Credit Facility (defined below) $ 6,000 $ 6,000 2018 Term Loan Facility (defined below) 20,000 20,000 Equipment financing loan 5,000 5,000 Debt issuance costs (488 ) (612 ) Total debt outstanding $ 30,512 $ 30,388 Less: current portion of long-term debt 9,087 — Long-term debt $ 21,425 $ 30,388

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 28, 2019
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity	The following table summarizes the Company’s stock option activity during the nine months ended September 28, 2019 : Number Weighted Weighted Aggregate Intrinsic Value (in thousands) (1) Outstanding at December 31, 2018 5,120,293 $ 3.13 7.3 $ 81,371 Granted 1,493,105 $ 36.61 — $ — Exercised (442,604 ) $ 2.06 — $ 33,440 Cancelled/Forfeited (83,625 ) $ 8.67 — $ — Outstanding at September 28, 2019 6,087,169 $ 11.34 7.3 $ 838,191 Vested and exercisable at September 28, 2019 3,233,150 $ 1.72 5.7 $ 474,955 Vested and expected to vest at September 28, 2019 4,503,505 $ 6.27 6.6 $ 641,908 __________ (1) Aggregate intrinsic value is calculated as the difference between the value of common stock on the transaction date and the exercise price multiplied by the number of shares issuable under the stock option.
Schedule of RSU activity	The following table summarizes the Company’s RSU activity during the nine months ended September 28, 2019 : Number of Shares Weighted Unvested at January 1, 2019 — $ — Granted 85,222 $ 169.48 Vested (101 ) $ 176.04 Unvested at September 28, 2019 85,121 $ 169.49
Schedule of restricted stock activity	The following table summarizes the Company’s restricted stock activity during the nine months ended September 28, 2019 : Number Weighted Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2018 100,127 1.6 $ 17.03 Granted 99,433 — $ 20.02 Vested/Released (62,626 ) — $ 19.21 Cancelled/Forfeited (23,333 ) — $ — Unvested at September 28, 2019 113,601 1.5 $ 19.49

Net Income (Loss) Per Share A_2

Net Income (Loss) Per Share Available to Common Stockholders (Tables)	9 Months Ended
	Sep. 28, 2019
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per common share	Computation of EPS for the nine months ended September 28, 2019 excludes the dilutive effect of 6,087,169 shares issuable under stock options and 85,121 RSUs, because the Company incurred a net loss and their inclusion would be anti-dilutive. Computation of EPS for the three and nine months ended September 29, 2018 excludes the dilutive effect of 4,807,941 shares issuable under stock options because the Company incurred net losses and their inclusion would have been antidilutive. (in thousands, except share and per share amounts) Three Months Ended Nine Months Ended September 28, September 29, September 28, September 29, Numerator: Undistributed net income (loss) available to common stockholders $ 4,090 $ (9,342 ) $ (11,991 ) $ (22,434 ) Undistributed net income available to nonvested restricted stockholders 9 — — — Net income (loss) available to common stockholders—basic 4,099 (9,342 ) (11,991 ) (22,434 ) Denominator: Weighted average common shares outstanding—basic 60,415,866 6,441,838 35,806,520 6,103,756 Dilutive effect of shares issuable under stock options 5,608,822 — — — Dilutive effect of RSUs 1,802 — — — Weighted average common shares outstanding—diluted 66,026,490 6,441,838 35,806,520 6,103,756 Net income (loss) per common share available to common stockholders—basic $ 0.07 $ (1.45 ) $ (0.33 ) $ (3.68 ) Net income (loss) per common share available to common stockholders—diluted $ 0.06 $ (1.45 ) $ (0.33 ) $ (3.68 )

Introduction (Details)

Introduction (Details) - USD ($) $ / shares in Units, $ in Millions	Aug. 05, 2019	May 06, 2019	Sep. 28, 2019	Jun. 29, 2019
Subsidiary, Sale of Stock [Line Items]
Underwriting discounts and commissions		$ 19.4
IPO
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)		11,068,750
Sale of stock, price per share (in dollars per share)	$ 160	$ 25
Proceeds from IPO, net		$ 252.4
Sale of stock, issuance costs		$ 4.9
Number of common stock shares converted		41,562,111
Number of shares issued for each share of convertible preferred stock converted (in shares)		1
Secondary Public Offering
Subsidiary, Sale of Stock [Line Items]
Proceeds from IPO, net	$ 37.5
Underwriting discounts and commissions	1.5
Sale of stock, issuance costs	$ 1
Selling stockholders sold (in shares)	3,487,500
Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	487,500	1,443,750
Selling stockholders sold (in shares)	250,000
Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of common stock shares converted				41,562,111
Common Stock | IPO
Subsidiary, Sale of Stock [Line Items]
Number of common stock shares converted			250,000	11,068,750
Number of shares able to purchase		160,767

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details)	Apr. 08, 2019USD ($)	Jan. 02, 2019	Mar. 02, 2016USD ($)	Dec. 31, 2016USD ($)	Feb. 28, 2016USD ($)shares	Oct. 31, 2015USD ($)	Sep. 28, 2019USD ($)shares	Sep. 29, 2018USD ($)$ / sharesshares	Sep. 28, 2019USD ($)shares	Sep. 29, 2018USD ($)$ / sharesshares	Jun. 29, 2019USD ($)	May 06, 2019USD ($)shares	May 05, 2019$ / sharesshares	Dec. 31, 2018USD ($)
Class of Warrant or Right [Line Items]
Stock split, conversion ratio		1.5
Deferred offering costs, incurred							$ 2,500,000		$ 2,500,000		$ 4,900,000
Accrued stock issuance costs									$ 0
Warrants outstanding (in shares) | shares							0		0
Liability for estimated sales discounts							$ 2,200,000		$ 2,200,000					$ 800,000
Cost of goods sold							59,178,000	$ 21,235,000	$ 133,123,000	$ 46,709,000
Stock options granted (in shares) | shares									1,493,105
Common Stock | Line of Credit | SVB Credit Facilities
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) | shares								60,002		60,002			60,002
Exercise price (in dollars per share) | $ / shares								$ 3		$ 3			$ 3
Series B
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) | shares								121,694		121,694			121,694
Exercise price (in dollars per share) | $ / shares								$ 1.07		$ 1.07			$ 1.07
Series E
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) | shares								39,073		39,073			39,073
Exercise price (in dollars per share) | $ / shares								$ 3.68		$ 3.68			$ 3.68
IPO
Class of Warrant or Right [Line Items]
Deferred offering costs, incurred							2,500,000		$ 2,500,000			$ 4,900,000		$ 2,400,000
IPO | Common Stock
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) | shares												160,767
Shipping and Handling
Class of Warrant or Right [Line Items]
Cost of goods sold							$ 3,400,000	$ 2,100,000	$ 7,400,000	$ 4,900,000
Distributor One | Customer Concentration Risk | Revenue Benchmark
Class of Warrant or Right [Line Items]
Concentration risk							17.00%	39.00%	19.00%	38.00%
Distributor Two | Customer Concentration Risk | Revenue Benchmark
Class of Warrant or Right [Line Items]
Concentration risk							15.00%	22.00%	18.00%	17.00%
Distributor Three | Customer Concentration Risk | Revenue Benchmark
Class of Warrant or Right [Line Items]
Concentration risk								13.00%		14.00%
International | Geographic Concentration Risk | Revenue Benchmark
Class of Warrant or Right [Line Items]
Concentration risk							14.00%	4.00%	12.00%	3.00%
Donald Thompson
Class of Warrant or Right [Line Items]
Consulting fees, related party									$ 0	$ 47,162
Consulting Agreement | Executive Chair
Class of Warrant or Right [Line Items]
Monthly transaction amount	$ 20,210.33
Advisor Agreement | Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Daily transaction amount						$ 4,000
Amended Advisor Agreement | Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Monthly transaction amount				$ 10,000	$ 25,000
Restricted Stock Unit | 2018 Plan | Executive Chair
Class of Warrant or Right [Line Items]
Restricted stock unit fair value			$ 105,000
Vesting period			12 months
Termination period upon prior written notice			120 days
Breach, termination period upon prior written notice, non-breaching party			30 days
Non-qualified Stock Option | Amended Advisor Agreement | Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Vesting period					3 years
Stock options granted (in shares) | shares					798,848
Minimum | Advisor Agreement | Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Days of service						2 days
Minimum | Amended Advisor Agreement | Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Days of service				5 days
Maximum | Amended Advisor Agreement | Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Days of service				6 days

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of financial instruments measured at fair value (Details) - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	$ 0	$ 1,918
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		1,918
Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		0
Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		0
Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		1,918
Preferred stock warrant liability | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability		1,441
Preferred stock warrant liability | Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability		0
Preferred stock warrant liability | Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability		0
Preferred stock warrant liability | Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability		1,441
Common stock warrant liability | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability		477
Common stock warrant liability | Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability		0
Common stock warrant liability | Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability		0
Common stock warrant liability | Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability		$ 477

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of changes in fair value (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance			$ 1,918	$ 550
Fair value of warrants issued during the period			0	248
Change in fair value of warrant liability	$ 0	$ 994	12,503	1,253
Reclassification of warrant liability to additional paid-in capital in connection with the IPO			(14,421)	0
Ending balance	$ 0	$ 2,051	$ 0	$ 2,051

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of net revenues by platform and channel (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
Disaggregation of Revenue [Line Items]
Less: Discounts	$ (10,041)	$ (2,833)	$ (19,263)	$ (6,659)
Net revenues	91,961	26,277	199,418	56,420
Retail
Disaggregation of Revenue [Line Items]
Net revenues	50,465	16,201	104,164	37,173
Restaurant and Foodservice
Disaggregation of Revenue [Line Items]
Net revenues	41,496	10,076	95,254	19,247
Gross Fresh Platform
Disaggregation of Revenue [Line Items]
Gross revenues	97,995	26,815	204,523	51,530
Gross Frozen Platform
Disaggregation of Revenue [Line Items]
Gross revenues	$ 4,007	$ 2,295	$ 14,158	$ 11,549

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018	Dec. 31, 2018
Restructuring and Related Activities [Abstract]
Restructuring expenses	$ 2,319	$ 528	$ 3,560	$ 1,170
Accrued unpaid liabilities, contract termination	$ 700		$ 700		$ 0

Inventories - Schedule of major

Inventories - Schedule of major classes of inventory (Details) - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials and packaging	$ 32,429	$ 13,756
Work in process	4,439	2,517
Finished goods	23,402	13,984
Total	$ 60,270	$ 30,257

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of property, plant, and equipment (Details) - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 53,701	$ 43,203
Less: accumulated depreciation and amortization	18,651	12,676
Property, plant and equipment, net	35,050	30,527
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	29,952	25,314
Research and development equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	7,786	6,088
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	7,468	7,080
Capital leases
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	883	882
Software
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	216	60
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	410	195
Vehicles
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	210	210
Assets not yet placed in service
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 6,776	$ 3,374

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 2,000	$ 1,400	$ 5,980	$ 3,046
Assets held-for-sale	8,900		8,900		$ 1,000
Cost of Goods Sold
Property, Plant and Equipment [Line Items]
Depreciation and amortization	1,400	1,000	4,200	2,400
Research and Development Expense
Property, Plant and Equipment [Line Items]
Depreciation and amortization	600	400	1,800	600
SG&A Expense
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 17	$ 3	$ 39	$ 3

Debt - Schedule of debt balance

Debt - Schedule of debt balances (Details) - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Debt issuance costs	$ (488)	$ (612)
Total debt outstanding	30,512	30,388
Less: current portion of long-term debt	9,087	0
Long-term debt	21,425	30,388
Loan Facility | 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, outstanding balance	20,000	20,000
Loan Facility | Equipment financing loan
Debt Instrument [Line Items]
Debt, outstanding balance	5,000	5,000
2018 Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Debt, outstanding balance	$ 6,000	$ 6,000

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2018	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018	May 06, 2019	May 05, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Debt issuance costs		$ 488,000		$ 488,000				$ 612,000
Amortization of debt issuance costs		$ 46,000	$ 16,000	$ 124,000	$ 51,000
Warrants outstanding (in shares)		0		0
Loan Facility | 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, outstanding balance		$ 20,000,000		$ 20,000,000				20,000,000
Loan Facility | Equipment financing loan
Debt Instrument [Line Items]
Debt, outstanding balance		5,000,000		5,000,000				$ 5,000,000
Interest expense		$ 100,000	19,000	$ 400,000	19,000
Interest rate		11.25%		11.25%				11.50%
Line of Credit | SVB Credit Facilities
Debt Instrument [Line Items]
Interest expense		$ 700,000	$ 300,000	$ 1,900,000	$ 300,000
Line of Credit | 2018 Term Loan Facility
Debt Instrument [Line Items]
Current borrowing capacity		$ 0		$ 0
Interest rate		9.00%		9.00%
Line of Credit | 2018 Revolving Credit Facility
Debt Instrument [Line Items]
Variable annual interest rate, additional upon default	5.00%
Debt, outstanding balance		$ 6,000,000		$ 6,000,000				$ 6,000,000
Current borrowing capacity		$ 0		$ 0
Interest rate		6.00%		6.00%
Advance at Closing | Loan Facility | 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, face amount	$ 10,000,000
Variable annual interest rate	4.00%
Advance at Closing | Loan Facility | 2018 Revolving Credit Facility
Debt Instrument [Line Items]
Debt, face amount	$ 6,000,000
Advance if no Event of Default through Borrowing Date | Loan Facility | 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, face amount	5,000,000
Advance if no Event of Default, Based on Minimum Level of Gross Profit | Loan Facility | 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, face amount	$ 5,000,000
Minimum | Line of Credit | 2018 Revolving Credit Facility
Debt Instrument [Line Items]
Variable annual interest rate	0.75%
Maximum | Line of Credit | 2018 Revolving Credit Facility
Debt Instrument [Line Items]
Variable annual interest rate	1.25%
Common Stock | Line of Credit | SVB Credit Facilities
Debt Instrument [Line Items]
Number of warrants issued (in shares)			60,002		60,002		60,002
Exercise price (in dollars per share)			$ 3		$ 3		$ 3
Series B
Debt Instrument [Line Items]
Number of warrants issued (in shares)			121,694		121,694		121,694
Exercise price (in dollars per share)			$ 1.07		$ 1.07		$ 1.07
Series E
Debt Instrument [Line Items]
Number of warrants issued (in shares)			39,073		39,073		39,073
Exercise price (in dollars per share)			$ 3.68		$ 3.68		$ 3.68
IPO | Common Stock
Debt Instrument [Line Items]
Number of warrants issued (in shares)						160,767

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) and Convertible Preferred Stock (Details) - $ / shares	May 06, 2019	Sep. 28, 2019	Aug. 05, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 31, 2018	Sep. 29, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Common stock, authorized (in shares)	500,000,000	500,000,000				58,669,600
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001				$ 0.0001
Convertible preferred stock, authorized (in shares)						43,882,867
Convertible preferred stock, par value (in shares)						$ 0.0001
Common stock, issued (in shares)		60,565,840				6,951,350
Common stock, outstanding (in shares)		60,565,840				6,951,350
Convertible preferred stock, outstanding (in shares)		0		0	41,562,111	41,562,111	39,486,895	39,486,895	39,474,156	39,361,211
Series A
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		0				3,333,500
Convertible preferred stock, par value (in shares)		$ 0.0001				$ 0.0001
Convertible preferred stock, issued (in shares)		0				3,333,500
Convertible preferred stock, outstanding (in shares)		0				3,333,500
Series B
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		0				4,802,260
Convertible preferred stock, par value (in shares)		$ 0.0001				$ 0.0001
Convertible preferred stock, issued (in shares)		0				4,680,565
Convertible preferred stock, outstanding (in shares)		0				4,680,565
Series C
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		0				8,076,643
Convertible preferred stock, par value (in shares)		$ 0.0001				$ 0.0001
Convertible preferred stock, issued (in shares)		0				8,076,636
Convertible preferred stock, outstanding (in shares)		0				8,076,636
Series D
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		0				8,713,207
Convertible preferred stock, par value (in shares)		$ 0.0001				$ 0.0001
Convertible preferred stock, issued (in shares)		0				8,713,201
Convertible preferred stock, outstanding (in shares)		0				8,713,201
Series E
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		0				4,740,531
Convertible preferred stock, par value (in shares)		$ 0.0001				$ 0.0001
Convertible preferred stock, issued (in shares)		0				4,701,449
Convertible preferred stock, outstanding (in shares)		0				4,701,449
Series F
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		0				4,866,776
Convertible preferred stock, par value (in shares)		$ 0.0001				$ 0.0001
Convertible preferred stock, issued (in shares)		0				4,866,758
Convertible preferred stock, outstanding (in shares)		0				4,866,758
Series G
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		0				5,140,257
Convertible preferred stock, par value (in shares)		$ 0.0001				$ 0.0001
Convertible preferred stock, issued (in shares)		0				5,114,786
Convertible preferred stock, outstanding (in shares)		0				5,114,786
Series H
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		0				4,209,693
Convertible preferred stock, par value (in shares)		$ 0.0001				$ 0.0001
Convertible preferred stock, issued (in shares)		0				2,075,216
Convertible preferred stock, outstanding (in shares)		0				2,075,216
IPO
Class of Stock [Line Items]
Number of common stock shares converted	41,562,111
Number of shares issued for each share of convertible preferred stock converted (in shares)	1
Convertible preferred stock, authorized (in shares)	500,000
Convertible preferred stock, par value (in shares)	$ 0.0001
Over-allotment option
Class of Stock [Line Items]
Selling stockholders sold (in shares)			250,000

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) - USD ($)	Aug. 01, 2019	Jun. 10, 2019	May 01, 2019	Apr. 30, 2019	Apr. 29, 2019	Apr. 18, 2019	Apr. 03, 2019	Nov. 15, 2018	Apr. 30, 2019	Oct. 31, 2018	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018	Dec. 31, 2018	Sep. 28, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)													1,493,105
Exercise price (in dollars per share)													$ 36.61
Stock options outstanding (in shares)											6,087,169		6,087,169		5,120,293	6,087,169
2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance				14,482,356					14,482,356
Stock options outstanding (in shares)											6,087,169		6,087,169		5,120,293	6,087,169
Shares issued (in shares)															4,335,331	4,854,085
Shares available for grant (in shares)											3,455,930		3,455,930		6,859	3,455,930
Beginning 2020 Fiscal Year | 2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized annually				2,144,521
Percent of common stock outstanding, per year				4.00%
Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense											$ 2,000,000	$ 300,000	$ 3,800,000	$ 1,000,000
Unrecognized compensation expense											$ 9,800,000		$ 9,800,000			$ 9,800,000
Unrecognized compensation expense, period of recognition													3 years 3 months 18 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)									99,433	135,791			99,433
Purchase price (in dollars per share)				$ 0.01					$ 0.01	$ 0.02
Fair value per share (in dollars per share)										$ 17.03	$ 19.49		$ 19.49		$ 17.03	$ 19.49
Shares issued (in shares)											113,601		113,601		100,127	113,601
Share-based compensation expense											$ 500,000	0	$ 1,300,000	0
Unrecognized compensation expense, period of recognition													1 year 6 months
Vesting period				24 months
Unrecognized share-based compensation expense											$ 2,500,000		$ 2,500,000			$ 2,500,000
Restricted stock price (in dollars per share)									$ 20.02				$ 20.02
Shares of restricted stock purchased by nonemployees (in shares)											113,601		113,601			113,601
Restricted Stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period										12 months
Restricted Stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period										24 months
Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)													85,222
Fair value per share (in dollars per share)											$ 169.49		$ 169.49		$ 0	$ 169.49
Shares issued (in shares)											85,121		85,121		0	85,121
Share-based compensation expense											$ 600,000	$ 0	$ 700,000	$ 0
Unrecognized compensation expense, period of recognition													3 years 7 months 6 days
Unrecognized share-based compensation expense											$ 3,800,000		$ 3,800,000			$ 3,800,000
Restricted stock price (in dollars per share)													$ 169.48
Restricted Stock Unit | 2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	14,862
Fair value per share (in dollars per share)	$ 176.04
Shares issued (in shares)											85,121		85,121		0	85,121
Employee Stock | 2018 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance								804,195
Additional shares authorized annually								536,130
Percent of common stock outstanding, per year								1.00%
Period of additional shares authorized								10 years
Employee | 2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)					48,999		264,033
Exercise price (in dollars per share)					$ 25		$ 20.02
Employee | Restricted Stock Unit | 2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		70,360
Fair value per share (in dollars per share)		$ 168.10
Nonemployee | Restricted Stock | 2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)						99,433
Purchase price (in dollars per share)						$ 0.01
Nonemployee | Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	12 months
Executive Officer | Employee | 2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)	5,073	125,000	50,000			1,000,000
Exercise price (in dollars per share)	$ 176.04	$ 168.10	$ 25			$ 25
Executive Officer | Employee | Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	48 months
Executive Officer | Employee | Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
First Anniversary | Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage													25.00%
First Anniversary | Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage													25.00%
Thereafter | Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period													3 years
Thereafter | Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period													3 years

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 28, 2019	Dec. 31, 2018
Number of Stock Options
Outstanding, beginning balance (in shares)	5,120,293
Granted (in shares)	1,493,105
Exercised (in shares)	(442,604)
Cancelled/Forfeited (in shares)	(83,625)
Outstanding, ending balance (in shares)	6,087,169	5,120,293
Weighted Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 3.13
Granted (in dollars per share)	36.61
Exercised (in dollars per share)	2.06
Cancelled/Forfeited (in dollars per share)	8.67
Outstanding, ending balance (in dollars per share)	$ 11.34	$ 3.13
Aggregate Intrinsic Value
Outstanding, beginning balance	$ 81,371
Granted	$ 0
Exercised	$ 33,440
Cancelled/Forfeited	$ 0
Outstanding, ending balance	$ 838,191	$ 81,371
Weighted Average Remaining Contractual Life (Years)
Weighted average remaining contractual life, outstanding	7 years 3 months 18 days	7 years 3 months 18 days
Weighted average remaining contractual life, vested and exercisable	5 years 8 months 12 days
Weighted average remaining contractual life, vested and expected to vest	6 years 7 months 6 days
Number of Stock Options, Vested and exercisable (in shares)	3,233,150
Number of Stock Options, Vested and expected to vest (in shares)	4,503,505
Weighted Average Exercise Price, Vested and exercisable (in dollars per share)	$ 1.72
Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)	$ 6.27
Aggregate intrinsic value, vested and exercisable	$ 474,955
Aggregate intrinsic value, vested and expected to vest	$ 641,908

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of restricted stock and RSU activity (Details) - $ / shares	1 Months Ended		9 Months Ended	12 Months Ended
	Apr. 30, 2019	Oct. 31, 2018	Sep. 28, 2019	Dec. 31, 2018
Restricted Stock Unit
Number of Shares of Restricted Stock
Outstanding, beginning balance (in shares)			0
Granted (in shares)			85,222
Vested (in shares)			(101)
Outstanding, ending balance (in shares)			85,121	0
Weighted Average Grant Date Fair Value Per Share
Weighted Average Grant Date Fair Value Per Share (in dollars per share)			$ 169.49	$ 0
Weighted Average Grant Date Fair Value Per Share, Granted (in dollars per share)			169.48
Weighted Average Grant Date Fair Value Per Share, Vested (in dollars per share)			$ 176.04
Restricted Stock
Number of Shares of Restricted Stock
Outstanding, beginning balance (in shares)			100,127
Granted (in shares)	99,433	135,791	99,433
Vested (in shares)			(62,626)
Cancelled/Forfeited (in shares)			(23,333)
Outstanding, ending balance (in shares)			113,601	100,127
Weighted Average Remaining Contractual Life (Years)
Weighted Average Remaining Contractual Life, Unvested (Years)			1 year 6 months	1 year 7 months 6 days
Weighted Average Grant Date Fair Value Per Share
Weighted Average Grant Date Fair Value Per Share (in dollars per share)		$ 17.03	$ 19.49	$ 17.03
Weighted Average Grant Date Fair Value Per Share, Granted (in dollars per share)	$ 20.02		20.02
Weighted Average Grant Date Fair Value Per Share, Vested (in dollars per share)			19.21
Weighted Average Grant Date Fair Value Per Share, Forfeited (in dollars per share)			$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	1 Months Ended
	Oct. 31, 2018defendant	Sep. 28, 2019USD ($)
Lease Obligations
Lease term		5 years
Aggregate lease amount		$ 2.7
Lease obligation due through 2023		2.4
Lease obligation due annually, 2019		0.5
Lease obligation due annually, 2020		0.5
Lease obligation due annually, 2021		0.5
Lease obligation due annually, 2022		0.5
Lease obligation due annually, 2023		0.5
Lease obligation due thereafter		0.1
Purchase commitments, total		68
Purchase commitments, due remainder of 2019		20
Purchase commitments, due 2020		24
Purchase commitments, due 2021		$ 24
Former Co-manufacturer Complaint | Pending Litigation
Lease Obligations
Number of defendants | defendant	1

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0	$ 21,000	$ 0
Accrued interest or penalties related to uncertain tax positions	$ 0		$ 0

Net Income (Loss) Per Share A_3

Net Income (Loss) Per Share Available to Common Stockholders - Narrative (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of stock equivalents resulting from stock options (in shares)	5,608,822	0	0	0
Dilutive effect of RSUs (in shares)	1,802	0	0	0
Antidilutive securities excluded from computation (in shares)				6,616,705
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)		4,807,941	6,087,169
Restricted Stock Unit
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	411		85,121

Net Income (Loss) Per Share A_4

Net Income (Loss) Per Share Available to Common Stockholders - Schedule of basic and diluted net loss per common share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
Numerator:
Undistributed net income (loss) available to common stockholders	$ 4,090	$ (9,342)	$ (11,991)	$ (22,434)
Undistributed net income available to nonvested restricted stockholders	9	0	0	0
Net income (loss) available to common stockholders—basic	$ 4,099	$ (9,342)	$ (11,991)	$ (22,434)
Denominator:
Weighted average common shares outstanding—basic	60,415,866	6,441,838	35,806,520	6,103,756
Dilutive effect of stock equivalents resulting from stock options (in shares)	5,608,822	0	0	0
Dilutive effect of RSUs (in shares)	1,802	0	0	0
Weighted average common shares outstanding—diluted	66,026,490	6,441,838	35,806,520	6,103,756
Net income (loss) per share available to common stockholders—basic (in dollars per share)	$ 0.07	$ (1.45)	$ (0.33)	$ (3.68)
Net income (loss) per share available to common stockholders—diluted (in dollars per share)	$ 0.06	$ (1.45)	$ (0.33)	$ (3.68)